Burnsil 25GM

100410200400301

Burnsil 25GM

45.00৳ 

Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)

Description

Indications

The topical prophylaxis against bacterial colonization and infection in burn sites is advised using Silver Sulfadiazine cream.

Other than burns, topical antibacterial therapy of certain polluted or infection-prone lesions.

Generic

Silver Sulfadiazine

Pharmacology

The antibacterial mechanism of Silver Sulfadiazine is still unknown. Following drug exposure, the bacterial cell membrane undergoes structural changes, including cell expansion and deformation, as well as a weakening of the cell wall membrane. In sensitive strains, this results in a reduction in viability. The silver moiety is attached to the bacterial cells when the silver sulfadiazine molecule dissociates. The silver moiety is thought to bond to deoxyribonucleic acid (DNA) after piercing the cell wall and inhibit bacterial cell multiplication. Mammalian cells have about 100 times the amount of DNA as bacterial cells. It is believed that racial tensions are the cause of the racial tensions.

Dosage & Administration

The burn wounds are cleansed, and Silver Sulfadiazine is applied over the burn wound. The burn areas should be covered with Silver Sulfadiazine at all times. The cream should be applied once to twice daily to a thickness of approximately 1/16 inches or 1.5 mm. Whenever necessary; the cream should be reapplied to any areas from which it has been removed by patient activity. If individual patient requirements make dressings necessary, they may be used. Reapplication should be ensured immediately after hydrotherapy. Treatment with Silver Sulfadiazine should be continued until satisfactory healing occurs, or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

Interaction

Enzymatic debriding agents: Because silver sulfadiazine can inactivate enzymatic debriding agents, using them together could be dangerous.

Oral hypoglycemic medications and phenytoin: The action of oral hypoglycemic agents and phenytoin may be potentiated in patients with large area burns when serum sulfadiazine levels may reach therapeutic values, and blood levels should be monitored.

Cimetidine: Co-administration of Cimetidine has been linked to an increased risk of leukopenia in individuals with large-area burns.

Contraindications

Patients who are hypersensitive to it or any of the other substances in the preparation should avoid it. It should not be used on pregnant women who are nearing or have reached term, preterm newborns, or newborn infants in the first two months of life.

Side Effects

In patients receiving Silver Sulfadiazine therapy, several occurrences of temporary leukopenia have been observed. Skin necrosis, erythema multiforme, skin coloring, burning sensation, rashes, and interstitial nephritis are other uncommon occurrences.

Pregnancy & Lactation

Pregnancy Classification B. Only if clearly justified should this medicine be taken during pregnancy, especially in pregnant women who are nearing or at term. Silver Sulfadiazine is not known to be eliminated in human milk. Considering the value of the drug to the mother, a decision should be made whether to quit nursing or discontinue the drug. Use in Children The safety and effectiveness of this medication in children have yet to be determined.

Precautions & Warnings

General: If hepatic and renal functions deteriorate and drug clearance diminishes, the buildup may occur, and cessation should be considered against the therapeutic benefit obtained. When considering the use of topical proteolytic enzymes in conjunction with it, keep in mind that silver has the potential to inactivate these enzymes.

Therapeutic Class

Topical Antibiotic preparations

Storage Conditions

Protect from light and moisture by storing in a cool, dry place below 30°C. Keep out of children’s reach.

Pharmaceutical Name

Beximco Pharmaceuticals Ltd.